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Efforts to increase advance care planning (ACP) for patients with serious illness are growing, including reimbursement introduced by the Centers for Medicare & Medicaid Services in 2016. ACP is especially important for older patients with advanced chronic kidney disease (CKD) because they face difficult decisions about dialysis initiation, often have poor prognoses, and frequently experience cognitive decline, limiting their ability to engage in treatment decision making.[@bib1], [@bib2], [@bib3] The 1-year mortality rate after dialysis initiation for adults older than 65 years is estimated at ∼30% using US Renal Data System data and at ∼54.5% using national representative survey data, with older non-Hispanic white patients and those with comorbid conditions faring worst.[@bib4]^,^[@bib5] Compared with patients with similarly complex conditions such as cancer, patients with advanced CKD experience more than double the rate of death in the intensive care unit (32.3% vs 13.4%), often contradicting patient preferences to die at home.[@bib6]

Although nearly a third of adults older than 60 years have CKD, their experiences with ACP have been understudied compared with patients with other high-mortality diseases.[@bib4]^,^[@bib5] The experiences of older adults with advanced CKD (stages 4-5 CKD) who are not receiving dialysis are particularly understudied, and evidence suggests that this non--dialysis-dependent population faces unique barriers to high-quality end-of-life care, such as tension with their clinicians over the decision to forgo dialysis and aligning care with patient goals.[@bib7]

There is increasing recognition that ACP may improve the quality of end-of-life care for patients with serious illnesses, particularly those with diminishing ability to engage in medical decisions.[@bib8]^,^[@bib9] Especially for patients with advanced CKD who wish to forgo dialysis, ACP can preserve patient autonomy by ensuring that patient values, goals, and preferences for care are communicated to clinicians before the development of incapacity or the need for urgent decision making.[@bib8] A systematic review of ACP interventions across a wide range of settings and illnesses found that ACP reduced hospitalizations, increased use of hospice, and increased compliance with patients' wishes.[@bib10] Among older adults with CKD and cardiovascular diseases, ACP improved shared decision making: a process in which patients, care partners, and clinicians discuss options for care in the context of patient values, preferences, and goals.[@bib11] ACP also increased patient and family satisfaction, reduced decisional conflict (uncertainty when making a choice), and improved family bereavement outcomes among elderly patients.[@bib12] Among the maintenance dialysis population, ACP also increased patient--care partner congruence in decision making.[@bib13]^,^[@bib14] Experiences among the non--dialysis-dependent advanced CKD population remain incompletely understood. This study aims to address that gap.[@bib7]

Despite the importance of ACP for older patients with advanced CKD, including those not receiving dialysis, and findings that most patients are eager to discuss their preferences, ACP rarely occurs until near death and often focuses on the less effective written advance directives rather than iterative discussion-based approaches.[@bib9]^,^[@bib10]^,^[@bib15], [@bib16], [@bib17], [@bib18] However, timely discussions of prognosis between patients and clinicians are associated with less emotional distress, increased patient trust in clinicians, and enhanced patient hope.[@bib10]^,^[@bib19]^,^[@bib20] Focusing on older non--dialysis-dependent patients with advanced CKD, this study examines patient and care partner preferences, perceptions, and experiences related to ACP. Understanding patient-centered values and preferences for ACP may improve strategies to support patients, decision-making surrogates, and clinicians, as well as clarify opportunities for improvement, particularly in the period before the decision to initiate or forgo dialysis.

Methods {#sec1}
=======

Core components of high-quality patient-centered ACP include prehospitalization discussion of patient preferences, prognostic discussion, documentation in the medical record, and organizational mechanisms to enable access to up-to-date written advance directives.[@bib21] [Figure 1](#fig1){ref-type="fig"} outlines ACP quality indicators and illustrates how key stakeholders (patients, care partners, and clinicians) can achieve shared decision making and high-quality patient-centered ACP. Drawing on this framework, we conducted a survey of patients older than 70 years with CKD stages 4 to 5 (non--dialysis-dependent) and their care partners to assess preferences, perceptions, and experiences with ACP (survey questions included as [Item S1](#appsec1){ref-type="sec"}). We also examined the degree to which care partners could accurately predict the end-of-life preferences of their loved ones by using 2 vignettes.[@bib14]Figure 1Interconnected components of high-quality patient-centered advance care planning (ACP) for patients with advanced chronic kidney disease. Informed by the Sinuff et al[@bib21] (2015) list of ACP quality indicators.

This study was approved by the Tufts Health Sciences Institutional Review Board (\#12345).

Data Collection {#sec1.1}
---------------

At 2 outpatient nephrology clinics in the greater Boston area, electronic health records were used to screen for eligible patients. Eligibility criteria included: English speaking, 70 years or older, advanced CKD (stages 4 or 5, non--dialysis-dependent), and \>15% risk for developing kidney failure according to the Kidney Failure Risk Equation with a time horizon of 5 years.[@bib22] Potentially eligible patients were either mailed information about the study or approached in person by study staff at clinic visits. Study coordinators met with eligible patients, explained the study, and consented interested patients.

Enrolled patients were asked to identify a care partner using a standardized validated social network question, asking them to name "someone with whom they discuss important matters" and who would be most likely to assist in decision making.[@bib23] These care partners were approached and consented following patient permission. Patients were interviewed in person following a routine nephrology or other clinical visit, while care partner interviews were completed by mail, telephone, or in person based on care partner preference. Trained interviewers read each question aloud to patients and recorded their responses, using visual aids as needed.

Measures {#sec1.2}
--------

Patient characteristics included self-reported demographics, laboratory results from medical record review, and results from the Kidney Disease Quality of Life (KDQOL-36) questionnaire, which assessed the effects and burdens of kidney disease on patients' quality of life.[@bib24] Patients self-reported their ability to perform instrumental activities of daily living and activities of daily living to assess independence and functional disability.[@bib25] The rest of the survey included questions to assess patients' understanding of advance directives, participation in ACP, and the Quality of Patient-Clinician Communication About End-of-Life Care scale.[@bib26] Developed for patients with AIDS, the 4-question instrument assessed communication between patients and clinicians by asking clinicians' level of understanding and care for patients and patient preferences. Answers of "no," "probably yes," and "definitely yes" were scored as 1, 2, and 3, respectively, yielding a range from 4 to 12 when summing the 4 questions, with higher scores suggesting better interactions about the quality of end-of-life care communications.

Cultural sensitivity questions assessed how strongly patients believed that their clinicians understood their values and respected them.[@bib27] To assess patients' and care partners' ACP experiences with clinicians, questions were adapted from the conceptual model of Sinuff et al[@bib21] and ranking of ACP quality indicators, many of which correlate to the Renal Physicians Association's clinical practice guidelines for shared decision making.[@bib21]^,^[@bib28] Last, to assess their care goals, patients and care partners independently answered whether in 2 hypothetical scenarios: (1) a sudden stroke or heart attack and (2) development of dementia, they would prefer either life-sustaining treatment (including dialysis) that delays death or comfort care.[@bib14] Comfort care was described as "For example, speaking to you about palliative care or treating symptoms like pain without trying to cure or control your underlying illness."

Statistical Analyses {#sec1.3}
--------------------

We used SPSS (version 25; IBM Corp) to perform descriptive analyses on survey data, determining the frequency and proportion of responses among patients and care partners. McNemar χ^2^ test compared care partner responses with those of the patient partners.

Results {#sec2}
=======

Sample Enrollment and Characteristics {#sec2.1}
-------------------------------------

Of 89 patients approached for participation (60 by mail and 29 in clinic), 51.7% of patients approached in clinic consented and 30% of patients consented following recruitment letters. All care partner participants were approached and surveyed in person when they accompanied their patient partners to clinic visits. In total, 42 participants (31 patients and 11 care partners) completed surveys. Mean patient age was 79±6.5 years, 67% were men, and 77% completed high school. Average estimated glomerular filtration rate was 20±4.9 mL/min/1.73 m^2^. All patients had difficulty with 1 or more instrumental activities of daily living, and 13% of patients had difficulty with 1 or more activities of daily living ([Table 1](#tbl1){ref-type="table"}).Table 1Sample CharacteristicsCharacteristicsAll Patients (n = 31)Patients Without Care Partners (n = 20)Patients With Care Partners (n = 11)Age, y79 ± 6.577 ± 6.279 ± 7.0Sex Men21 (68%)13 (65%)8 (73%) Women10 (32%)7 (35%)3 (27%)Race White24 (77%)14 (70%)10 (91%) Black or African American4 (13%)4 (20%)0 (0%) Asian1 (3.2%)0 (0%)1 (9%) Native American or Alaskan Native1 (3.2%)1 (5%)0 (0%) Other2 (6.5%)2 (10%)0 (0%)Married or living with partner16 (52%)9 (45%)7 (64%)Unmarried15 (48%)11 (55%)4 (36%)Highest level of education \<High school7 (23%)4 (20%)3 (27%) High school6 (19%)3 (15%)3 (27%) Some college5 (16%)4 (20%)1 (9%) College or postgraduate13 (42%)9 (45%)4 (36%)Annual household income \<\$25,0005 (16%)3 (15%)2 (18%) \$25,000-\$50,0007 (23%)3 (15%)4 (36%) \>\$50,00015 (48%)10 (50%)5 (45%) Not specified5 (16%)5 (25%)0 (0%)Difficulty with ≥1 ADL4 (13%)1 (5%)3 (27%)Difficulty with ≥1 IADL31 (100%)20 (100%)11 (100%)eGFR, mL/min/1.73 m^2^20 ± 4.921 ± 5.018 ± 4.0KDQOL-36: Effects of Kidney Disease score86 ± 1588 ± 1582 ± 13KDQOL-36: Burden of Kidney Disease score77 ± 2580 ± 2471 ± 27[^1][^2]

Knowledge and Completion of Advance Directives {#sec2.2}
----------------------------------------------

Nearly half (48%) the patients reported knowing what an advance directive was. After being provided a definition, 65% of patients stated that they had an advance directive. The most commonly cited reason for not having an advance directive among patients was not knowing what an advance directive was (18%) or having never thought about signing one (11%). Among those who had an advance directive, 68% had a durable power of attorney for health care and 32% had a living will. Access to advance directives was commonly limited to a patient's family (57%), whereas 17% stated that their lawyer or clinician had access. Overall, 32% of patients stored their advance directive at home compared with 25% at the hospital and 21% with their family. Only 7% indicated that their advance directive was stored in their medical record.

Most (81%) patients had designated a surrogate decision maker in writing, and 58% of patients had discussed their preferences for life-sustaining treatments with their surrogate decision maker. However, only 16% of patients had discussed preferences for life-sustaining treatments with their nephrologist, and 19% had discussed their preferences for life-sustaining treatments with other health care clinicians (ie, a nurse, social worker, or spiritual care). Care partners were more likely than patients to say that they or the patient had discussed the patient's advance directives, including preferences for life-sustaining treatments, with their clinicians (*P* = 0.04).

Patient Beliefs and Trust in Clinicians {#sec2.3}
---------------------------------------

Patients in general reported high levels of trust in their clinician's judgments about their medical care (m=9.1±2.1, from 0-10) when assessing this clinician's judgments about their medical care. Mean score for the Quality of Patient-Clinician Communication About End-of-Life Care scale was 10±1.6 (from 4-12). Most (68%) patients said that their clinician "definitely" cared about them, 68% believed that their clinician listened to them in these discussions, and 77% believed that their clinician gave them sufficient attention. In a set of questions examining cultural sensitivity, 61% said that they "strongly agreed" that their clinician understood their background and values and 87% "strongly disagreed" that their clinician lacked respect for them and the way they lived their lives ([Table 2](#tbl2){ref-type="table"}).Table 2Quality of Patient-Clinician Communication About End-of-Life Care and Cultural SensitivitySurvey MeasurePatient Attitudes (n = 31)Definitely YesProbably YesNoClinician knows treatment preferences12 (40%)16 (50%)3 (10%)Clinician cares about patient21 (68%)10 (32%)0 (0%)Clinician listens to what patient has to say21 (68%)10 (32%)0 (0%)Clinician gives patient enough of his or her attention24 (77%)6 (19%)1 (3%)PoorFairGoodVery GoodExcellentOverall quality of ACP conversations4 (15%)6 (22%)5 (19%)6 (22%)6 (22%)Strongly AgreeSomewhat AgreeSomewhat DisagreeStrongly DisagreeCultural sensitivity Clinician understands my values19 (61%)8 (26%)2 (6.5%)2 (6.5%) Clinician looks down on me0 (0%)1 (3%)3 (10%)27 (87%)[^3][^4]

Quality and Experience With ACP Discussions {#sec2.4}
-------------------------------------------

Despite high levels of trust, more than a third (37%) of patients rated conversations with nephrologists about their end-of-life treatment preferences "poor" or "fair." Moreover, only 40% of patients thought their nephrologist "definitely" knew the kinds of treatment they would want if they became too sick to speak for themselves ([Table 3](#tbl3){ref-type="table"}). Few (26%) patients in our survey had engaged in discussions about prognosis. Just 16% of patients reported discussing the outcomes, benefits, and burdens (or risks) of life-sustaining medical treatments with their clinicians. Still fewer (10%) patients had been involved in discussions about preferences for conservative care. A quarter (23%) of patients received help from their health care team accessing legal documents to communicate their advance care plans, and just 7% of patients and their families recalled being offered the opportunity to discuss issues around capacity to engage in decision making and consent to care. Only 16% of patients recalled having been asked by a clinician about what was important to them, such as values, spiritual beliefs, or other practices as they consider health care decisions, and about half (45%) of patients indicated that they were given the opportunity to express their fears or concerns. A minority (39%) of patients indicated that they were given the opportunity for clarification questions, and 42% of patients indicated that they had been informed that they could change their mind regarding goals of care decision making ([Table 3](#tbl3){ref-type="table"}).Table 3Patient Experiences of Advance Care Planning Discussions with CliniciansHas a member of the clinical team talked to you about...All Patients (n = 31)Patients Without Care Partners (n = 20)Patients With Care Partners (n = 11)Care Partners (n = 11)YesNoYesNoYesNoYesNoPrognosis8 (26%)22 (71%)5 (25%)14 (70%)3 (27%)8 (73%)1 (9%)9 (82%)Outcomes of life-sustaining medical treatments5 (16%)26 (84%)4 (20%)16 (80%)1 (9%)10 (91%)3 (27%)7 (64%)Outcomes of conservative care3 (10%)28 (90%)2 (10%)18 (90%)1 (9%)10 (91%)4 (36%)6 (55%)You and your family meeting with the clinician to discuss treatment options6 (19%)24 (77%)4 (20%)15 (75%)2 (18%)9 (82%)6 (55%)4 (36%)Prior discussions or documents regarding life-sustaining treatments5 (16%)24 (77%)4 (20%)14 (70%)1 (9%)10 (91%)7 (64%)2 (18%)What is important to you/your loved ones regarding health care decisions at this stage of your life5 (16%)25 (81%)4 (20%)15 (70%)1 (9%)10 (91%)4 (36%)5 (46%)Your fears or concerns14 (45%)16 (52%)11 (55%)8 (40%)3 (27%)8 (73%)6 (55%)2 (18%)Any questions or clarifications regarding your overall goals of care12 (39%)17 (55%)7 (35%)11 (55%)5 (45%)6 (55%)5 (46%)4 (36%)Treatments you prefer to have or not have if you develop a life-threatening illness6 (19%)24 (77%)5 (25%)14 (70%)1 (9%)10 (91%)3 (27%)4 (36%)The option to change your mind regarding decisions around the goals of care13 (42%)16 (52%)10 (50%)8 (40%)3 (27%)8 (73%)4 (40%)3 (30%)An opportunity to discuss capacity and consent with regard to advance care planning2 (7%)26 (84%)2 (10%)15 (75%)0 (0%)11 (100%)3 (27%)5 (46%)Support from the allied health care team as needed?2 (75%)29 (93%)2 (10%)18 (90%)0 (0%)11 (100%)6 (55%)5 (46%)"Goals of care discussion" information to look at before conversations with the clinician?3 (10%)26 (84%)3 (15%)15 (75%)0 (0%)11 (100%)4 (36%)5 (46%)Accessing legal documents to communicate you/your loved one's Advance Care Plans?7 (23%)24 (77%)5 (25%)15 (75%)2 (18%)9 (82%)3 (27%)8 (73%)[^5]

Most questions about patient experiences with clinicians were answered similarly among patients and their care partners, but care partners were more likely to say that a clinician had offered to arrange a family meeting (*P* = 0.04) and more likely to say that they had been asked by a clinician about prior discussions or written documents about the use of life-sustaining treatment (*P* = 0.01). Care partners were also more likely to say that their loved one had been offered support from the allied health care team (*P* = 0.03).

Goals of Care Concordance Among Patients and Care Partners {#sec2.5}
----------------------------------------------------------

Two hypothetical scenarios (stroke/heart attack or development of dementia) were presented to patients and care partners, using a measure developed and used in other studies with older patients with CKD.[@bib14] In each scenario, 84% and 81% of patients, respectively, preferred a focus on comfort care over life-prolonging treatment. None of the care partners preferred for the patient to delay death in either scenario, although many (44% and 22%, respectively) reported uncertainty. In comparing care partner and patient responses, there was usually agreement on focusing on comfort as the preferred approach, with the exception of 2 patients preferring life-prolonging treatment in the first scenario while their care partners preferred otherwise or were unsure ([Table 4](#tbl4){ref-type="table"}).Table 4Patient and Care Partner Concordance on Goals of CareAll Patients (n = 31)Patients Without Care Partners (n = 20)Patients With Care Partners (n = 11)Care Partners (n = 9)Stroke or heart attack Goals of care should be focused on delaying death2 (6%)1 (5%)1 (9%)0 (0%) Goals of care should be focused on comfort and peace26 (84%)18 (90%)8 (73%)5 (56%) I am not sure3 (10%)1 (5%)2 (18%)4 (44%)Dementia Goals of care should be focused on delaying death1 (3%)0 (0%)1 (9%)0 (0%) Goals of care should be focused on comfort and peace25 (81%)17 (85%)8 (73%)7 (78%) I am not sure5 (16%)3 (15%)2 (18%)2 (22%)

Discussion {#sec3}
==========

Our findings align with prior literature in demonstrating the need for ACP among patients with CKD, especially before they reach the decision to initiate dialysis given that the non--dialysis-dependent population faces unique barriers to patient-centered ACP.[@bib2]^,^[@bib3]^,^[@bib7]^,^[@bib9] In our study of older adults with advanced non--dialysis-dependent CKD, most believed that clinicians knew their preferences for treatment if their condition were to progress, though few had actually discussed this with their clinicians. Patients reported high levels of trust and communication quality with clinicians, consistent with findings for patients with other complex chronic diseases.[@bib26] Despite this, most patients reported ACP communication experiences that did not satisfy ACP quality indicators.[@bib10]^,^[@bib19], [@bib20], [@bib21] Most had not discussed possibilities of changing their mind or losing the ability to consent to care and few had discussed values or been offered help to complete written advance directives. This highlights an opportunity for improvement: high levels of trust among patients with advanced CKD in their clinicians should be buttressed by increased communication about ACP.[@bib29] These conversations are especially important to protect the autonomy of patients who opt to forgo dialysis.

Nephrology clinicians are critical to ACP because they can facilitate a discussion of prognosis and disease trajectory with patients and families. Though challenging, these conversations may improve end-of-life outcomes and reduce emotional distress.[@bib19] However, few patients had discussed prognosis with their clinicians despite evidence that patients want to know their prognosis even when their predicted outcomes are not desirable.[@bib18] Reluctance to discuss prognosis with patients with advanced CKD may be partly due to limited CKD-specific validated tools estimating life expectancy needed to assist clinicians in providing effective and compassionate guidance.[@bib30]^,^[@bib31] Studies demonstrate that for patients with serious illness such as advanced cancer, discussion of prognosis is associated with more realistic patient expectations and has not been shown to harm patients' emotional well-being or patient-physician relationships.[@bib32] Lack of training in having ACP conversations, time constraints, and loss of revenue from foregoing dialysis may also deter clinicians from engaging patients in ACP.[@bib33]

Involving family in ACP discussions is also critical to shared decision making because they may know and understand the patients' values, goals, and preferences. Our results demonstrate that some patients who have not engaged in ACP discussions with their clinicians may already be discussing ACP with loved ones, highlighting a missed opportunity for clinicians to engage both patients and care partners in decision making. Among our participants, more patients had formally designated a surrogate decision maker than had completed a written advance directive. Most patients had discussed the use of life-sustaining treatment with their surrogate decision maker (often a family member), whereas few patients discussed this with clinicians. However, ACP has been demonstrated to be most effective when clinicians introduce the topic and promote shared decision making with the patient and his or her family, leading to greater patient and family satisfaction and congruence and reduced decisional conflict.[@bib11]^,^[@bib12]^,^[@bib14]

Our findings also demonstrate that patients and their care partners do not always remember discussions with clinicians similarly. In a systematic review of the effect of ACP on surrogate decision makers for patients with chronic illnesses, at least one-third experienced negative emotional burdens, including stress, guilt, and doubt, which were often substantial and long lasting.[@bib34]^,^[@bib35] Facilitating ACP communication between the patient-family-clinician triad to ensure that surrogate decision makers know which treatment is consistent with patients' preferences can reduce the emotional burden on surrogate decision makers.[@bib31]^,^[@bib34] This reinforces the need for iterative discussions over time and for starting ACP conversations earlier, before decision making is needed. Clinicians should attempt to engage patients and their families together because improved shared decision-making efforts could increase patients' understanding of their disease and care options, as well as improve concordance and help all members of the patient-family-clinician triad have a mutual understanding of the patients' preferences and treatment path.

Last, when presented with specific scenarios in which longer life would be associated with substantial negative impacts on quality of life, this study showed that nearly all patients and care partners expressed a preference for focusing on comfort over delaying death as a care goal. This is consistent with previous research demonstrating that patients who experience appropriate ACP are more likely to receive conservative care in alignment with their wishes and less likely to die in a hospital.[@bib36] Thus, the integration of ACP into usual care for older patients with advanced CKD and their care partners presents an important opportunity to delineate patients' goals, values, and preferences to best tailor and align their future care. Among patients already receiving dialysis, ACP is associated with an increased propensity for dialysis withdrawal, a finding that likely demonstrates how ACP can increase patient knowledge of alternatives to dialysis and improve congruence of care with patient wishes because many of these patients may prefer conservative care over dialysis.[@bib13] Given that many patients with advanced CKD start or prepare to start dialysis despite significant comorbid conditions or advanced age, improving ACP could potentially prevent unwanted high-intensity treatment or a pathway for withdrawal for advanced-stage patients for whom conservative care may better align with their goals and preferences.[@bib37]^,^[@bib38]

Study strengths include a wide and comprehensive range of questions that assessed both perceptions and experiences regarding ACP, and that patient and care partner responses were directly compared. In addition, the method of individual 1-on-1 surveys allowed for clarifications to be made when necessary and for the patients to go at their own pace, reducing response bias and increasing patient comfort.

Our study is not without limitations, including enrolling moderate- to high-functioning older adults without severe cognitive issues and with overall high education levels, a small sample size, and 35% response rate. In addition, all participants lived in the greater Boston area and many were white men, limiting generalizability. For the survey question of patient trust in their clinicians, the high reported level of trust had a strong ceiling effect, limiting its accuracy. Questions regarding patient attitudes were measured on a scale that was loaded toward a positive answer, and the ACP conservation quality rating question did not include a not applicable response for participants who may not have had any ACP conversations. The simplicity of the hypothetical goals of care scenarios may not be directly applicable to real life. Additionally, the statistical comparisons between patient and care partner responses should be interpreted with caution owing to the small sample size of care partners.

Currently, our team is leading the Decision-Aid for Renal Therapy (DART) trial ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} [NCT03522740](NCT03522740){#intref0015}), a larger multisite study examining the comparative effectiveness of an interactive web-based decision aid to help older patients with advanced CKD and their care partners choose treatment aligned with their preferences and complete ACP. The DART study aims also to extend the findings of this study to the wider and more diverse population of older adults with advanced CKD.

Though patients perceive that their clinicians understand their treatment wishes, this perception often does not align with the completion of key ACP steps during end-of-life care discussions. Clinicians should communicate prognosis and include both patients and families in ACP discussions, especially because these conversations often already occur in the patient-family context and this dyad may have some differences in their perceptions of clinical interactions. With the July 2019 announcement of the Advancing American Kidney Health Initiative,[@bib39] upcoming models likely will include greater incentives and improved reimbursement for patient and care partner education and for conservative and palliative care options. By focusing on key ACP steps, clinicians may be able to improve concordance between patient preferences and treatment received and congruence between patients and care partners, as well as increase the numbers of patients who have written advance directives, ultimately resulting in more patient-centered care.
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**Item S1:** Survey questions.

[^1]: *Note.* Numbers reflect the frequency with which each response was selected. Values expressed as mean ± standard deviation or number (percent), unless otherwise noted. The survey measures have been abbreviated for clarity.

[^2]: Abbreviations: ADL, activity of daily living; eGFR, estimated glomerular filtration rate; IADL, instrumental activity of daily living; KDQOL-36; Kidney Disease Quality of Life questionnaire.

[^3]: *Note.* Numbers reflect the frequency with which each response was selected. Values expressed as number (percent). The survey measures have been abbreviated for clarity.

[^4]: Abbreviation: ACP, advance care planning.

[^5]: *Note.* Numbers reflect the frequency with which each response was selected. Values given as number (percent). The survey measures have been abbreviated for clarity.
